Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Biosciences, Inc. on July 2, 2020. The filing discloses the termination of a material definitive agreement with DePuy Synthes Sales Inc. regarding the co-promotion of EXPAREL (bupivacaine injectable suspension) for orthopedic procedures in the United States.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The only specific financial data disclosed relates to the termination of the co-promotion agreement:
- Early Termination Payment: The Company expects to pay DePuy an additional early termination payment in 2021 estimated in the range of $7 million to $12 million.
- Payment Basis: This payment is calculated based on a percentage of EXPAREL commissions earned by DePuy during 2020.
- Ongoing Commissions: DePuy will continue to receive commissions on EXPAREL sales for the remainder of 2020.
Material Changes
The primary material change is the termination of the Co-Promotion Agreement dated January 24, 2017. The agreement will officially terminate on January 2, 2021. This change was initiated by Pacira Biosciences exercising its right to terminate the agreement after three years of the effective date with six months' notice.
Outlook, Risks, and Management Commentary
Management indicated that the companies will work together through the remainder of 2020 to support EXPAREL and ensure a smooth transition. The filing includes standard forward-looking statements regarding the estimated termination payment, noting that actual results may differ materially due to various risks and uncertainties. These risks are referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.
Key Facts for Investor Verification
- Verify the exact calculation methodology for the $7 million to $12 million early termination payment in future filings.
- Monitor the impact of the transition on EXPAREL sales volumes and marketing expenses post-January 2021.
- Review the Company's cash flow projections to assess the liquidity impact of the 2021 termination payment.
- Confirm the status of the transition plan and any potential operational disruptions to the orthopedic product line.